This significant discovery validates the overexpression of PGRMC1 and S2R in pancreatic cancer, as previous research has demonstrated that small-molecule inhibitors can target PGRMC1 [51]. Similarly, S2R has been targeted with small-molecule inhibitors in the treatment of pancreatic cancer [49,51]. Here, TMEM97 is linked to familial pancreatic carcinoma.